Kornimate/medical-research-clean huggingface dataset:
molecular detection of advanced neoplasia in pancreatic cysts

Conditions: Pancreas Cyst

Summary: researchers are trying to find out whether new tests ("biomarkers") of blood, stool, pancreas cyst fluid, or pancreas juice can be used to diagnose malignant or pre-malignant changes in pancreas cysts.

subjects with fukuoka worrisome (fw) or fukuoka high risk (fhr) pancreatic cysts will be enrolled and assigned to immediate surgery or clinical follow-up groups based on clinical management as determined by the treating physicians. blood, stool, pancreas cyst fluid, and pancreas juice specimens will be collected from participants.

Eligibility criteria:
inclusion criteria: * patients with pancreatic cystic lesions meeting fukuoka worrisome or fukuoka high-risk criteris * patients with suspected cystic neoplasm of the pancreas * able to provide written informed consent exclusion criteria: * pregnant and/or nursing * incarceration * imaging showing possible pancreatic cancer * prior history of pancreatic cancer or pancreatic surgery * history of receiving systemic chemotherapy or abdominal radiation within the last 5 years * previous therapy for a pancreatic cystic lesion * history of pancreatic necrosis * diagnosis of cancer (other than non-melanoma skin cancer) within the last 5 years
safety, tolerability, and pharmacokinetics of iloperidone depot in schizophrenic patients

Conditions: Schizophrenia

Summary: this study is designed as a 3-part trial to evaluate the safety of a novel depot formulation of iloperidone, compare 2 depot dosage forms, and perform dose ranging of 1 chosen form in support of a monthly depot dosing regimen. in phase a, the study is designed to evaluate the safety of a crystalline iloperidone depot formulation. in phase b, the pharmacokinetic and safety profile of 2 depot clinical dosage forms will be compared, and 1 form will be selected for assessment in phase c. phase c of this study is designed to define the dose-exposure relationship of the selected form and to provide information that will permit a comparison of the risk-benefit ratio of several doses of the study drug to enable optimal dose selection for later studies.


Eligibility criteria:
inclusion criteria: * patients with schizophrenia that have been stable for 3 months. exclusion criteria: * women who can become or are currently pregnant or lactating. * hypersensitivity to iloperidone or related drugs. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: schizophrenia iloperidone depot injection
does provision of point of care cd4 technology and early knowledge of cd4 levels affect early initiation and retention on anti-retroviral treatment (art) in hiv positive pregnant women in the context of option b+ for pmtct?

Conditions: HIV/AIDS

Summary: the study will be conducted at 32 health care facilities in three provinces in zimbabwe and will compare the impact of the provision point of care cd4 technology and early knowledge of cd4 levels on retention at 12 months, with or without poc cd4 and a programmatic mentoring package. option b+ will be implemented at all sites and 16 intervention sites will receive poc cd4 machines and visits from a team of clinical mentors. the study also aims to assess rates of art initiation and time to art initiation of hiv positive pregnant women in settings implementing option b+ with or without poc cd4 and related counselling/support; rates of retention in care of hiv positive mothers at 6 months post art initiation in settings implementing option b+ with or without poc cd4 and related counselling/support; rates of art initiation and retention at 6 and 12 months post art initiation according to different levels of cd4 count; cost of retaining hiv positive pregnant women until 6 and 12 months; acceptability and feasibility of poc cd4 as an adjunct to good clinical care of hiv positive pregnant women.


Eligibility criteria:
inclusion criteria: * pregnant at the time of booking * hiv positive diagnosis * not on art at the time of booking * present up to 38 weeks into gestation * presents more than 48 hours prior to delivery exclusion criteria: * already on art at booking * presents more than 38 weeks into gestation or less than 48 hours prior to delivery

Keywords: prevention of mother to child transmission pmtct option b+ art retention loss to follow up time to initiation poc cd4 clinical mentoring costing hiv aids zimbabwe
ffa metabolism in different types of human obesity

Conditions: Obesity

Summary: we will give intravenous fat molecules to help us understand how the fat that is released from peoples fat cells is used. this will be done when people are eating, not eating and walking.


Eligibility criteria:
inclusion criteria: bmi 28-36 -upper body obesity and lower body obesity non-obese bmi 19-24. females premenopausal. must be a non-smoker. exclusion criteria: bp\> 160/95 on htn meds, known systemic illness. medications that affect fat metabolism. we do no cover travel expenses. known heart and vascular disease.
recurrent failures in assisted reproductive techniques (the first registry)

Conditions: Infertility

Summary: assisted reproductive technologies (arts) are widely used in couples with fertility problems. however, despite art treatment options have evolved over time, the implantation rate remains rather low. a possible role for inherited and acquired thrombophilias has been invoked, especially in women with previous implantation failures. however, several factors could play a role in these conditions. a potential benefit of low-molecular-weight heparin (lmwh) in improving art outcomes, independently of the presence of thrombophilia, has been recently suggested. this register is designed in order to better define all possible variables influencing art outcome and improve clinical management of women with previous implantation failures. during this study the investigators will collect and evaluate clinical data regarding the first cycle in women with previous art failures.


Eligibility criteria:
inclusion criteria: * 2 or more implantation failures/losses of clinical pregnancies after art * art cycle at enrolment * informed consent exclusion criteria: * ovarian hypofunction * uterine pathology * hydrosalpinges * previous inclusion in the study
pantoprazole and docetaxel for men with metastatic castration-resistant prostate cancer

Conditions: Prostate Cancer

Summary: the main objectives of this trial are: 1. to assess the activity and safety of pantoprazole and docetaxel (with prednisone) in men with metastatic crpc who have not received prior chemotherapy. 2. to evaluate archival prostate cancer tissue of men included in the clinical trial for evidence of autophagy using ihc for lc3b, atg5, p62 as well as erg. 3. to evaluate pharmacokinetic interactions of pantoprazole with docetaxel.


Eligibility criteria:
inclusion criteria: * age ≥18yrs * ecog performance status ≤2 * histologically or cytologically confirmed adenocarcinoma of the prostate * clinical or radiological evidence of metastatic disease * disease progression while receiving androgen deprivation therapy with an increase in psa of 25% or greater over nadir value measured on 3 consecutive occasions at least 1 week apart * antiandrogen therapy must have been stopped at least 4 weeks prior to start of trial treatment (6 weeks in the case of bicalutamide or nilutamide)if there was a reduction in serum psa after this therapy was initiated * baseline serum prostate-specific antigen (psa)≥10ng/ml * total testosterone \<50 ng/dl (\<1.7 nmol/l) * adequate hematologic values: neutrophil count ≥1,500/mm3, platelet ≥100,000/mm3, hemoglobin ≥10.0 g/dl * adequate hepatic and renal function: total bilirubin level ≤1.5 x uln (unless secondary to documented gilbert's disease); alt,ast, and creatinine ≤1.5 x uln * ability to understand and to sign consent for the study exclusion criteria: * prior treatment for prostate cancer with chemotherapy or radioisotopes * history of another cancer within the preceding five years (except basal or squamous-cell skin cancer or adequately treated superficial bladder cancer) * known or suspected brain or leptomeningeal metastases * symptomatic peripheral neuropathy of grade 2 or higher * major surgery within 4 weeks of start of trial treatment * radiotherapy to ≥25% of the bone marrow and any radiotherapy within 4 weeks of start of trial treatment * known hypersensitivity to trial treatment or hypersensitivity to any of its components * any concomitant drugs contraindicated for use with the trial treatment * any serious underlying medical condition which could impair the ability of the patient to participate in the trial * any psychological, familial, sociological or other patient related factors that might preclude compliance with the study protocol

Keywords: metastatic
identifying molecular determinants of infertility in men (modify)

Conditions: Male Infertility

Summary: the purpose of this study is to understand the underlying mechanisms of infertility caused by unknown factors. the investigator propose to identify small non-coding rna (sncrna) biomarkers of infertility and advance towards developing a more accurate and robust approach for infertility diagnosis.

the goal of the study is to identify small non-coding rna signatures of infertility in men through the comparison of sperm sncrna profiles from around 100 men (21-50 years of age). the participants will be classified into fertile and infertile groups by the conventional method. through the project, the investigator intends to understand the underlying mechanisms of idiopathic infertility. by utilizing semen as liquid biopsy, through sperm sncrna profiling and comparison (infertile vs fertile). the investigator proposes to identify the sncrna (mirnas, pirnas and trfs) as biomarkers of infertility. the investigator proposes to generate a validated signature of sncrnas that will help in selecting high quality sperms for ivf.

Eligibility criteria:
inclusion criteria * male, aged 21 - 50 years old * proficient in english language * willing to comply to study protocol * able to provide written informed consent exclusion criteria * current and/or previous diagnosis of tuberculosis, acquired immunodeficiency syndrome (aids), and other sexually transmitted diseases * experiencing severely limited mobility (eg. wheelchair bound, need walking aid) * diagnosed with severe unstable mental conditions (eg. dementia, or cognitive impairment) * alcohol or drug abuse
tools to improve medication continuity in adolescents with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: medication is an efficacious treatment strategy for adolescents with attention-deficit/hyperactivity disorder (adhd), however use significantly declines during adolescence when the consequences of adhd are most severe (e.g. dropping out of school, delinquency, etc.). the unified theory of behavior change (utbc) has been proposed as a conceptual model to explain the mechanism underlying adhd medication adherence and to guide the development of interventions to improve the continuity of treatment. the utbc is a well-established and empirically tested model that identifies factors that influence an individual's intention to perform a behavior as well as factors that influence whether a behavior is actually carried out. indeed, the research team's preliminary data support the relevance of pre-intention factors and implementation factors for medication continuity among adolescents with adhd. currently, no evidence-based interventions target medication continuity for adolescents with adhd. the objective of this study is to test a multi-component intervention that systematically identifies and targets aspects of the utbc model most relevant for each adolescent with poor adhd medication continuity. the central hypothesis is that the tailored intervention will support adhd medication continuity. the study will conduct an open label trial among adolescents with poor medication continuity to test whether the intervention engages the mechanism underlying medication continuity and improves outcomes.


Eligibility criteria:
inclusion criteria: * first prescribed adhd medicine more than one year prior to enrollment * registered on myadhdportal.com at practice participating in study * filled at least one prescription for a stimulant medication in the past year exclusion criteria: * more than 80% of days covered with medicine over past one year * poor understanding level: the participant and parent cannot understand or follow instructions given in the study.
anti-inflammatory efficacy of ginger containing dentifrice in the control of biofilm induced gingivitis

Conditions: Gingivitis

Summary: the goal of this clinical trial is to test efficiency of using toothpaste containing (ginger) over a period of three month to control on gingival inflammation and plaque accumulation through measuring the clinical periodontal parameters (gingival index (gi), bleeding on probing (bop) and modified quigley-hein plaque index (mqhpi ) in comparison with colgate total toothpastes in patients with biofilm induced gingivitis.

objectives: 1. measuring the clinical periodontal parameter (gingival index) and salivary cytokine il-1β and superoxide dismutase sod over a period 3 months before and after using capitano (ginger containing) and colgate total toothpastes for patients with gingivitis. 2. measuring the clinical periodontal parameter ((gingival index (gi), bleeding on probing (bop) and modified quigley-heinplaque index (mqhpi )) over a period 3 months before and after using capitano (ginger containing) and colgate total toothpastes for patients with gingivitis by elisa. 3. correlation between ( interleukin 1 beta and sod) and clinical periodontal parameters

Eligibility criteria:
inclusion criteria: 1. subjects aged 20-35 who will volunteer to participate. 2. apparently good general health. 3. patients with gingivitis (having ≥30% bleeding sites with no ppd \>3 mm, intact periodontium and no loss of periodontal attachment). 4. those with a minimum of 20 natural teeth. exclusion criteria: * 1. those with chronic disease, immunocompromised patients, pregnant, on contraceptive and lactating women. 2. those currently using any mouthwash. 3. those on antibiotic therapy and anti-inflammatory medications during the study and at the last 2 months before the study. 4. those having a history of hypersensitivity to any product used in the present study. 5. those with a recent tooth extraction. 6. those having periodontitis. 7. those who smoker or alcoholism. 8. those with extensive untreated dental caries, diseases of hard and soft palate and subjects wearing orthodontic appliances, removable dentures, implant, crown and bridge or presenting with abnormal salivary flow.
a study to evaluate lumasiran in patients with advanced primary hyperoxaluria type 1

Conditions: Primary Hyperoxaluria Type 1; Primary Hyperoxaluria

Summary: the purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (pk), and pharmacodynamics (pd) of lumasiran in patients with advanced primary hyperoxaluria type 1 (ph1).


Eligibility criteria:
inclusion criteria: * has documented diagnosis of primary hyperoxaluria type 1 (ph1) * estimated glomerular filtration rate (egfr) ≤45 ml/min/1.73 m\^2 for patients ≥12 months of age (\<12 months of age, must have serum creatinine considered elevated for age) * meets plasma oxalate level requirements * if taking vitamin b6 (pyridoxine), must have been on stable regimen for at least 90 days * if on dialysis, may be on hemodialysis therapy only and must have been on a stable regimen for at least 4 weeks exclusion criteria: * hemodialysis/peritoneal dialysis combination therapy or peritoneal dialysis alone * diagnosis of conditions other than ph1 contributing to renal insufficiency * history of liver transplant * history of kidney transplant and currently receiving immunosuppressants

Keywords: ph1 primary hyperoxaluria hyperoxaluria rnai therapeutic sirna agt systemic oxalosis
personalized transcranial direct current stimulation in stroke recovery

Conditions: Stroke

Summary: the central objective of this application is to explore the neural substrate of personalized tdcs (ptdcs) and to determine whether the paradigm for each stroke patient can predict the amount of sustained clinical improvement through increased connectivity as measured by a biomarker of plasticity.

this is a randomized, sham controlled double masked parallel group study with optional crossover of chronic (\>3mo from stroke onset) ischemic or hemorrhagic stroke patients to test the effect of ptdcs on a cerebral connectivity biomarker of plasticity during stimulation and after 10 treatment of up to 2 ma ptdcs. ptdcs will be performed during the first 20 minutes of occupational therapy targeting the weaker arm compared to sham. patients will have the option to cross over after the completion of 1-month follow-up and will complete the same procedures with real tdcs if they were in the sham group.

Eligibility criteria:
inclusion criteria: * symptomatic ischemic or hemorrhagic stroke verified by computerized axial tomography or magnetic resonance imaging resulting in hemiparesis (mrc 1-4). * age more than 18, male or female, all racial and ethnic groups * entry into the study \>3 months post onset * modified ashworth scale score \<3 in the involved upper extremity * passive range of motion within functional ranges at the shoulder, elbow, wrist and hand * able to follow 2 step commands exclusion criteria: * patients with history of severe alcohol or drug abuse, psychiatric illnesses like severe depression, poor motivational capacity, or severe language disturbances, particularly of receptive nature or with serious cognitive deficits (defined as unable to follow study instructions). * patients with bilateral paresis, or weakness or sensory damage due to peripheral causes (e.g. peripheral nerve injury, muscle or orthopedic injury etc.) * patients with severe uncontrolled medical problems (e.g. cardiovascular disease, severe rheumatoid arthritis, active joint deformity of arthritic origin, active cancer or renal disease, any kind of end-stage pulmonary or cardiovascular disease, or a deteriorated condition due to age,epilepsy or others). * patients with unstable cardiac arrhythmia. * pregnancy * patients with metallic implants in the head, patients with pacemakers, patients with craniotomies, including burr holes who cannot be safely stimulated * patients with seizures * non-english speaking individuals will only be eligible if they can provide the appropriate translator for all the sessions of the study as no funding is available to pay for such services.
contribution of a high-resolution diffusion sequence at 3t for the detection of acute punctate ischemic brain lesions

Conditions: Stroke

Summary: stroke is a public health issue and a priority for our institution. mri plays an essential role in the management of stroke, its contribution being diagnostic, etiological and prognostic. among the mri sequences used in stroke emergencies, the diffusion sequence plays a key role in highlighting ischemic lesions as early as the hyperacute phase, even though the other sequences in the protocol do not reveal any anomaly. this sequence alone conditions the management of patients, particularly in the context of "thrombolysis emergencies". it has been shown that the sensitivity of the diffusion sequence for the detection of ischemic lesions can directly depend on acquisition parameters such as b value, slice thickness or spatial resolution. recent advances in mri now allow us to perform diffusion sequences with higher spatial resolution. the matrix is an important acquisition parameter of mri sequences defining the ability of the sequence to distinguish 2 pixels in the acquisition plane. the higher the matrix, the higher the spatial resolution of the sequence in the acquisition plane. at the saint-joseph hospital, we have a new 3t mri since september 2020 allowing the acquisition in clinical routine of a more resolved diffusion sequence: 160x200 matrix ("high resolution" diffusion, hr), against 128x140 ("standard" diffusion usually). these two sequences are acquired in particularly short acquisition times (1 minute 37 seconds). this hr diffusion sequence is performed as part of routine care since september 2020 for specific situations: absence of lesion highlighted on the standard diffusion sequence while the patient has a suggestive symptomatology (especially for lesions of the brainstem), search for lesion in other vascular territories (thus in favor of an embolic origin) in a patient who presents an isolated ischemic lesion or ischemic lesions in a single territory. it has been reported in the literature that increasing the spatial resolution can reveal small lesions that were not visible on more conventional sequences. there is a clear rationale for seeking to improve the detection of small lesions (\<5 mm) because their detection may have important therapeutic implications for many patients (particularly in the context of thrombolysis emergencies, transient ischemic attacks, or amnesic strokes).


Eligibility criteria:
inclusion criteria: * patients with age ≥ 18 years * patients who underwent a 3t brain mri for suspected stroke/tia (mri performed within 7 days of clinical symptomatology) and for whom the "hr" diffusion sequence was considered useful for diagnosis * french-speaking patient exclusion criteria: * patient under guardianship or curatorship * patient deprived of liberty * patient under court protection * patient objecting to the use of his data for this research
impact of an instrumented measurement on a performance assessment in cerebral palsy treatment

Conditions: Cerebral Palsy

Summary: the goal of this study is to assess the impact of passive reflective markers on bimanual performance assessment scores in children with unilateral cerebral palsy. the main questions it aims to answer are: * is it possible to instrument performance assessment without changing the functionnal behaviour of the patient ? * how is this behavious modified ? during their usual occupational therpy assessment at the cmcr massues, participants will do a second bimanual performance assessment with passive reflection markers taped on their trunk, humerus and forearm. the glocal scores and sub items scors of both instrumented and non instrumented assessment will be compared.


Eligibility criteria:
inclusion criteria: * unilateral cerebral palsy * with an occupational therapy assessment planed with the duration of the study exclusion criteria: * severe cognitive impairment

Keywords: quantified motion analysis performance assessment bimanual performance unilateral cerebral palsy